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Abstract
Type 1 diabetes (T1D) tends to cluster in families, suggesting there may be a genetic component predisposing to disease.
However, a recent large-scale genome-wide association study concluded that identified genetic factors, single nucleotide
polymorphisms, do not account for overall familiality. Another class of genetic variation is the amplification or deletion of
.1 kilobase segments of the genome, also termed copy number variations (CNVs). We performed genome-wide CNV
analysis on a cohort of 20 unrelated adults with T1D and a control (Ctrl) cohort of 20 subjects using the Affymetrix SNP Array
6.0 in combination with the Birdsuite copy number calling software. We identified 39 CNVs as enriched or depleted in T1D
versus Ctrl. Additionally, we performed CNV analysis in a group of 10 monozygotic twin pairs discordant for T1D. Eleven of
these 39 CNVs were also respectively enriched or depleted in the Twin cohort, suggesting that these variants may be
involved in the development of islet autoimmunity, as the presently unaffected twin is at high risk for developing islet
autoimmunity and T1D in his or her lifetime. These CNVs include a deletion on chromosome 6p21, near an HLA-DQ allele.
CNVs were found that were both enriched or depleted in patients with or at high risk for developing T1D. These regions
may represent genetic variants contributing to development of islet autoimmunity in T1D.
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Introduction
Type 1 diabetes (T1D) results from immune-mediated selective
destruction of pancreatic islet cells resulting in insulin deficiency
and hyperglycemia [1,2]. Symptoms of polydipsia, polyuria,
polyphagia and weight loss manifest when significant numbers of
islet cells have been destroyed. However, antibodies to islet
autoantigens can be detected in peripheral blood prior to clinical
disease[1,3]. With early diagnosis of disease or assessment of risk,
immune therapy may impede islet destruction and preserve insulin
production, delaying onset of clinical manifestations[2].
Another component of T1D that aids in our understanding of
the disease and assessment of risk is genetic inheritance. A long-
term (up to 40 year) study of twin pairs in Finland revealed a
monozygotic (MZ) pairwise concordance for T1D of 27.3% while
the concordance for dizygotic (DZ) twins was 3.8%[4]. The impact
of genetics was further made clear in this study because upon
diagnosis of T1D in one twin, the length of time to diagnosis in the
other twin in the concordant pairs was a maximum of 6.9 years in
MZ twins and 23.6 years in DZ twins[4]. In addition to measur-
ing incidence of T1D in twin studies, islet antigen-specific
autoimmunity can also be determined. As a precursor to T1D,
autoimmunity is defined as the presence of antibodies to islet
autoantigens in sera[5]. In another study, 83 unaffected monozy-
gotic twins were followed for nearly 44 years and incidence of
autoimmunity or diagnosis of T1D was recorded. This study
showed a 65% cumulative incidence of T1D by 60 years of age
and more than 75% tested positive for an islet autoantibody
during the course of the study. Once autoimmunity was
established, the risk of diabetes was 89% within 16 years of the
first positive autoantibody test.
Clearly genetics play an important role in the T1D disease
process as both MZ and DZ twins have the same environmental
exposures but different concordance rates and length to diagnosis
of the second twin. Numerous genes have been associated with
T1D, the most significant being the HLA region on chromosome
6[6]. More than 90% of type 1 diabetics carry HLA alleles DR3-
DQ2 or DR4-DQ8 compared to no more than 40% of the general
population[7]. Alleles at HLA-DQB1 are known to be, in part,
protective[8]. Single nucleotide polymorphisms (SNPs) are also
associated with T1D. A recent genome-wide association study of
approximately 2,000 patients with each of 7 common, chronic
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association of SNPs in 5 previously identified regions with T1D
and discovered 5 novel associations. However, the authors
concluded that these regions, with the exception of the HLA on
chromosome 6, confer only modest effects on T1D, and ‘‘the
association signals so far identified account for only a small
proportion of overall familiality’’[9]. These results suggest that
additional genetic variants contribute to inheritance of T1D.
Another class of genetic variation is the amplification or deletion
of .1 kilobase segments of the genome, also called copy number
variations (CNVs)[10,11]. Gene duplications were first identified in
the pathogenesis of Charcot-Marie Tooth disease in the 1980s; a
copy number amplification of the PMP22 gene was shown to be
sufficient to cause disease[12]. These regions of variance were
thought to be rare and when the human genome was published,
variance amongst humans was primarily attributed to base-pair level
SNPs[13,14]. However, copy number variants were discovered to be
present and widespread in the genome shortly thereafter[10,11].
These variants are generated during normal recombination events,
leading to inherited CNVs, as well as somatically throughout life in
rapidly dividing cells[15,16,17]. CNVs can directly influence gene
expression through dosage effects where more copies of the gene
produces greater expression, and also by altering the transcriptional
regulation of the genome, both of the region of variance itself and
regions up to 1 megabase away[18,19,20].
Monozygotic twins discordant for disease represent a controlled
population in which to identify potentially disease-associated
CNVs. Monozygotic twins do not have identical genetic sequences
and are known to vary in CNVs and at the epigenetic
level[21,22,23,24]. Differences may arise during prenatal cell
division or post-natally in continuously dividing cells like
lymphocytes. The latter would result in CNVs that not only differ
from the co-twin but also from CNVs in other cells and tissues of
the body. In the case of disease discordant monozygotic twins, if a
CNV were associated with a certain disease, we presume the twin
affected by the disease would have the variant and the unaffected
twin would not. A study of nine MZ twin pairs discordant for
Parkinson’s disease identified 35 regions of variance present in
only the affected twin of at least four of those pairs, confirming the
hypothesis that MZ twins differ in CNVs and that these regions
may be involved in the development of disease, as evidenced by
the presence of specific CNVs in multiple affected twins[22].
There are numerous other diseases and states associated with
differences in CNVs, among them schizophrenia and bipolar
disorder[25]. But not all CNV associations are with neurologic or
behavioral diseases. Recent studies have shown additional
functional implications of CNV and disease, notably in studies of
CNV of the Fc-gamma receptor and the autoimmune disease
systemic lupus erythematosus (SLE). Patients with SLE are more
likely to have fewer copies of FCGR3B, encoding a protein
involved in the uptake and clearance of immune complexes[26].
We hypothesize that CNVs contribute to susceptibility to and/or
protection from T1D. To test this hypothesis, we performed
genome-wide analysis on a cohort of 20 unrelated adults diagnosed
with T1D and 20 unrelated control (Ctrl) subjects to identify CNVs
either enriched or depleted in the T1D cohort compared to Ctrl.
We then lookedat the frequency of these variants ina second cohort
of 10 MZ twin pairs disease discordant for T1D. The frequencies of
the CNVs of interest did not differ from the affected twin subset to
the unaffected twin subset. However, because of the high lifetime
incidences of autoimmunity and/or T1D in the unaffected twins,
the 10 twin pairs were considered as a single cohort with or at high
risk for T1D[3]. This analysis identified 5 CNVs enriched and 4
CNVs depleted in both the T1D and Twin cohorts.
Results
We sought to determine if CNVs are associated with T1D by
performing genome-wide CNV analysis on a cohort of 20 patients
with T1D and 20 Ctrl patients using the Affymetrix SNP Array
6.0. An additional cohort of 10 monozygotic twin pairs discordant
for T1D was analyzed for validation purposes. Quality of the
hybridization, as defined by Affymetrix in the Genotyping Console
as a contrast QC ,0.4, was assessed and 1 Ctrl sample failed prior
to copy number analysis.
Of primary importance in the analysis of these data was the
validity of our copy number calling algorithm. Raw data from all 3
cohorts, 59 Affymetrix arrays in total, were inputted into the
Birdsuite programs and copy numbers were called across the
genome. The Birdsuite software determined integer copy numbers
of predefined regions of common variance (copy number
polymorphisms, CNPs) and employed a more complex, multi-
dimensional model to identify rare variants [27]. Output files
contain copy number values across the chromosome with a
confidence score of each individual call (Table S1). Genome wide
call rates were also estimated for each individual sample. Two
samples from the unrelated adult T1D cohort failed a quality
control checkpoint of call rate greater than 98%. The remaining
57 arrays had call rates $ 98.6%. We compared copy numbers
determined by the Birdsuite analysis to copy numbers determined
by quantitative PCR (qPCR) in 37 samples of genomic DNA
across 5 distinct chromosomal regions (Table S2). For qPCR
experiments, Applied Biosystem’s CopyCaller1.0 program deter-
mined a non-integer copy number based upon the DDCt
calculation and then predicted an integer copy number, each
with an associated confidence value. For 185 separate experimen-
tal points, there was .96% agreement in copy number
determinations made by the Birdsuite analysis and the qPCR
analysis (Figure 1).
For the analysis, we first catalogued all confident, variant CN
calls on chromosomes 1–22 within the framework of known copy
Figure 1. Percent agreement between Birdsuite copy number
calls and qPCR. Percent agreement between the Affymetrix array
copy numbers, as determined by the Birdsuite software, and qPCR copy
number, determined using DDCt calculations, is plotted for each copy
number class. Percents are based on 214 comparisons from copy
numbers for 37 samples on 6 distinct chromosomal regions (7q33,
8q11, 8q24, 15p13, 16p12). For copy number 0, 6/6 samples agreed
(100%). For copy number 1, 45/45 samples agreed (100%). For copy
number 2, 127/134 of samples agreed (94.7%). The overall agreement is
178/185 samples (96.2%).
doi:10.1371/journal.pone.0015393.g001
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number variance present in greater than 1% of the 270 HapMap
samples, resulting in a library of 1,320 CNPs. Novel CNVs not
represented in the CNP library were also identified and included
in the analysis.
A single CNV is capable of causing disease. In the case of
Charcot Marie Tooth disease type 1, 70% of patients have one
singular pathogenic variant[12,29]. In a more common disease,
like T1D, we hypothesized that a single undiscovered variant
would not be present and pathogenic at a percentage as high as
70%, rather we set the threshold of variance within each diabetes
group at roughly half that, or 40%. Additionally, to ensure
selection of variants differentially expressed between the two
groups, we further limited the classification of enrichment in T1D
to those CNVs present at a 1.5 fold greater frequency than Ctrl.
Conversely, a CNV was classified as depleted in T1D if it was
present in .40% of the Ctrl cohort at a 1.5 fold greater frequency
than T1D.
Variants in the T1D group were compared to those in the Ctrl
group and 18 CNPs present in . 40% of the T1D cohort at a 1.5
fold greater frequency than the Ctrl cohort were identified as
enriched in T1D. Conversely, 20 CNPs and 1 novel CNV were
depleted in the T1D cohort, defined as a variant present in .40%
of the Ctrl cohort at a 1.5 fold greater frequency than the T1D
cohort. These 39 CNVs were then studied in a second cohort.
The Affymetrix chip determines copy number based on values
of nearly 1,000,000 probes in the genome, resulting in a high
probability for both type I and II errors. To help control for these
errors, we performed genome-wide copy number analysis in a
second cohort of patients, monozygotic twin pairs discordant for
T1D. We hypothesized that the 39 CNVs identified in the first
T1D:Ctrl comparison may be differentially present in this second
cohort of MZ twins. For each twin, confident variant calls were
catalogued in the CNP library as before. CNVs present in only 1
twin of a pair were isolated and grouped based on disease status
(affected or unaffected). These variants were compared to the 39
CNVs from the previous analysis and no overlap was found.
Additionally, there were no CNVs present in more than 2 affected
or unaffected twins of the pairs when this cohort was considered
independently of the previous analysis.
The unaffected twin in each of these MZ twin pairs will have a
greater than 75% lifetime incidence of developing islet autoanti-
bodies and 65% of these now-unaffected twins will go on to
develop T1D in their lifetime[3]. As such, CNVs may be enriched
in this group as a whole that confer risk to developing islet
autoimmunity or T1D. Alternatively, the CNVs depleted in the
unrelated adult T1D cohort may also be depleted in the twin
cohort as a whole. The 10 MZ twin pairs were compared to the
Ctrl cohort to determine CNVs that were enriched or depleted in
the Twin group. Criteria for enrichment and depletion were
identical to those outlined above. A total of 49 CNPs were
enriched and 23 CNVs were depleted in the Twin cohort. Of the
depleted CNVs, 22 were CNPs while 1 novel CNV was identified.
All together, 72 CNVs were enriched or depleted in the Twin
cohort.
The 72 CNVs identified in the Twin cohort were compared to
the 39 CNVs identified in the adult T1D cohort to identify CNVs
present in both cohorts. Of these, 10 CNVs were enriched in both
cohorts relative to Ctrl and 11 CNVs were depleted. Based upon
permutation testing (with 1000 permutations), the p-value or
probability of observing 10 or more overlapping CNVs in these
cohorts by chance is 0.005 (=5/1000).
The 21 CNVs were further classified to select those CNVs
greater than 1,000 base pairs in length and identified by at least 3
consecutive probes on the Affymetrix array. A total of 9 CNVs (8
CNPs, 1 novel CNVR) met these criteria. Of these, 5 CNPs were
enriched in the T1D and Twin cohorts and are identified by their
CNP ID (Table 1). These CNPs are located on 5 different
chromosomes, range in size from 1,400 base pairs to 14,000 base
pairs and are deletions to copy numbers of 0 or 1. Frequencies in
the T1D and Twin cohorts range from 50% to 95% with
corresponding frequencies in the Ctrl cohort from 21% to 58%.
CNP253, on chromosome 2p11, contains part of a non coding
RNA, NCRNA00152. CNP1303 contains the gene SNTG1,
encoding gamma syntrophin, a cytoplasmic peripheral membrane
protein known to be expressed in brain. Two regions, CNP934
and CNP1162, contain at least one segment of DNA longer than
100 bp with more than 70% evolutionarily conserved sequence to
mus musculus as determined by the ECR browser, defined as an
evolutionarily conserved noncoding sequence[30]. Each of these
sequences encodes at least one potential transcription factor
binding site suggesting these regions may have regulatory function.
The sequence encompassed by CNP1956 is not gene coding
and does not contain an evolutionarily conserved noncoding
sequence.
Four CNVs were depleted in the T1D and Twin cohorts
relative to Ctrl (Table 2). The 3 CNPs are gene coding regions
located on 3 different chromosomes, span 3,400 base pairs to
15,900 base pairs and are also all copy number deletions to 0 or 1.
The frequency of the CNVs depleted in the diabetes cohorts range
from total absence (0%) to 39%. The frequency of these CNPs in
the Ctrl cohort ranged from 42%–68%. CNP1102 contains a
deletion of TYW1, encoding a protein involved in stabilizing
ribosomal decoding processes. CNP1879 is in the region coding
for the ankyrin repeat and sterile alpha motif domain gene,
ANKS1B, and the chromosome 17 CNP2240 contains coding
sequence for TRIM16.
The novel CNV, A588, depleted in both T1D and Twin cohorts
is located on chromosome 15 and spans more than 1.3 million
base pairs. It manifests as both an amplification and deletion and
contains coding regions for genes like the golgin family members
GOLGA6L6 and GOLGA8C, B cell CLL/Lymphoma gene BCL8
and an ankyrin domain family member, POTEB. The frequency of
this variant in the Ctrl group is 58%, T1D group 33% and only
10% in the Twin cohort. Interestingly, many of the variants in this
region do not span the entirety of the more than 1 million base
pairs (Figure 2), rather we see a preponderance of overlapping and
non-overlapping variants clustered in this region. Because a single
variant can impact regulation and expression of a gene more than
1 megabase away, these variants were grouped together as one
singular CNV region (CNVR) [19].
The CNVs enriched and depleted in our cohorts are potentially
associated with autoimmunity so we assessed the frequency of
these variants in cohorts of 21 patients with rheumatoid arthritis
(RA), and 50 patients with multiple sclerosis [22] (Figure 3). The
T1D enriched CNPs 253, 934, 1162 and 1303 also meet the
criteria for enrichment in RA; additionally, CNP1162 and
CNP1303 were significantly enriched in the MS cohort
(Figure 3a). The frequency of CNP1956 did not meet the criteria
for enrichment in RA or MS. For those CNVs depleted in T1D,
we similarly assessed their frequency in the RA and MS cohorts
(Figure 3b). CNPs 1879, 2240 and the novel CNVR, A588, were
also depleted in RA and MS. The depletion of CNVR A588 in RA
was significant along with the depletion of CNP2240 in both RA
and MS. CNP1102 was depleted in T1D and RA, but not MS
(Figure 3b). Thus, a portion of CNVs enriched or depleted in T1D
are found at similar frequencies in subjects with other autoimmune
diseases.
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of variance could be seen in larger, independent cohorts of cases
and controls. Copy number at the T1D enriched CNPs 1162,
1303 and 1956 was determined by qPCR in a group of 73 Ctrl
subjects and 73 subjects with T1D, independent of previous
cohorts (Figure 4). While frequency of variance did not differ
appreciably between the two groups at CNPs 1162 and 1956, the
difference of variance at CNP 1303 approached significance
(p=0.0655). Independent validation of 3 CNPs enriched in T1D
showed one region that may continue to be of interest as a
potential pathogenic variant.
Discussion
We identified 9 CNVs enriched or depleted in 2 independent
cohorts of patients with T1D or at high risk for developing disease
relative to a Ctrl cohort. These CNVs represent amplifications and
deletions and contain both known genes and evolutionarily
conserved non-coding sequences. The regions containing these 9
CNVs were cross referenced with a list of T1D associated SNPs
generated from recent reports and The National Human Genome
Research Institute[9,31,32]. The only CNV region to have a
corresponding SNP association is CNP934 located on chromo-
some 6p21, the major histocompatibility complex (MHC). The
copy number variant region is specifically in the vicinity of HLA-
DQA1; DQ alleles have long been associated with susceptibility to
and protection from T1D[33]. Additionally, copy number
variance in the HLA region has previously been reported in the
literature[34].The duplication of this finding in a small cohort of
patients indicates the importance of the MHC region on
chromosome 6 in the genetic susceptibility to T1D and affirms
that analysis of small sample sizes can yield biologically relevant
results. Additionally, because of the limited overlap of SNPs and
CNVs, this study establishes the two as independent classes of
genomic variants associated with T1D.
In addition to CNP934 on chromosome 6, four other CNVs
were enriched in patients with T1D and unaffected twins at high
risk to develop islet-specific autoimmunity and diabetes. At least 2
of the unaffected twins already test positive for islet autoantibodies.
This information indicates that the 5 CNPs enriched in these
groups, while they are not beacons of clinical disease, may be
involved in the formation of islet autoantibodies, or autoimmunity.
Enrichment or depletion of certain of these CNPs in clinically
distinct additional autoimmune diseases supports this view.
CNP1303 encodes SNTG1, a candidate gene for scoliosis[35].
Deletions of two evolutionarily conserved non-coding sequences
on chromosomes 6 and 7 could lead to dysregulation of any
number of genes near the variant region on each chromosome.
Underlying mechanisms by which copy number deletions at these
regions and others may contribute to autoimmunity remains to be
determined.
Three regions enriched in T1D were further analyzed by qPCR
in independent cohorts of Ctrl and T1D patients, CNPs 1162,
1303 and 1956. CNPs 1162 and 1956 did not differ in their
variance between the Ctrl and T1D independent cohorts.
CNP1303 however, is variant in a greater number of T1D
subjects than Ctrl and is barely shy of the criteria for enrichment
with a fold change difference of 1.48. The difference in variance
also approaches statistical significance. One reason the variance
seen in the independent cohorts might have trended the same
Table 1. CNVs enriched in T1D and Twin cohorts, relative to Ctrl.
CNP ID
a Chr Start End
Amplification or
Deletion Ctrl% T1D%
Ctrl:
T1D p
b Twin%
Ctrl:
Twin p Sequence
253 2p11 87,600,933 87,609,093 deletion 42 72 0.13 70 0.15 NCRNA00152
934 6p21 32,700,999 32,710,085 deletion 42 89 0.01 65 0.26 CNS
c
1162 7q33 133,435,735 133,449,694 deletion 37 78 0.03 80 0.02 CNS
1303 8q11 51,194,577 51,195,974 deletion 21 61 0.03 50 0.12 SNTG1
1956 13q21 71,375,556 71,378,557 deletion 58 89 0.08 95 0.02 -
aCNP ID as defined in McCarroll, et al. Nature Gen 40(10):1166-74.
bp-value derived from chi-square analysis.
cCNS= Conserved Noncoding Sequence, defined as a region .100bp with at least 70% similarity to sequence in mus musculus (as determined by ECR browser,
ecrbrowser.dcode.org).
doi:10.1371/journal.pone.0015393.t001
Table 2. CNVs depleted in T1D and Twin cohorts, relative to Ctrl.
CNP ID
a Chr Start End
Amplification or
Deletion Ctrl% T1D% Ctrl:T1D p
b Twin% Ctrl:Twin p Sequence
1102 7q11 66,266,764 66,282,667 deletion 68 39 0.14 10 0.001 TYW1
1879 12q23 98,319,424 98,322,865 deletion 47 22 0.20 10 0.02 ANKS1B
A588
c 15q11 18,491,920 19,803,369 both 58 33 0.24 10 0.004 BCL8, POTEB,
GOLGA6L6,
GOLGA8C
2240 17p12 15,483,886 15,487,515 deletion 42 22 0.35 0 0.004 TRIM16
aCNP ID as defined in McCarroll, et al. Nature Gen 40(10):1166-74.
bp-value derived from chi-squared analysis.
cA588 is a novel variant identified in this study.
doi:10.1371/journal.pone.0015393.t002
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that our primary analysis is influenced heavily by the cohort of
monozygotic twins. The affected twin of each pair was diagnosed
with T1D as a child while the independent T1D cohort are adult
patients with T1D who were diagnosed at varying ages. Thus,
patients with an earlier onset of T1D may have a greater
likelihood of possessing the CNP1303 variant.
Additionally, 4 CNVs were less likely to be variant in the T1D
and Twin cohorts relative to the Ctrl group. One potential
consequence of these CNVs is that normal regulation and
expression of these genes contributes to the T1D disease process.
Alternatively, differential expression induced by variance may
confer some sort of protection to the patients in the Ctrl cohort.
CNVR A588 on chromosome 15 represents a unique class of
variant. Both amplifications and deletions of varying lengths are
observed with an increased frequency of variance in T1D. CNVs
can affect expression levels of genes within 1 megabase of the
variant through positional effects, by deletion or amplification of
distal regulatory elements or other poorly understood mechanisms.
An amplification of a promoter may cause increased expression of
a certain gene. Deletion of an inhibitory element in that same
region could also produce increased expression of that same gene.
This T1D depleted CNVR contains as many as 26 gene coding
regions and cDNA clones[36]. Preservation of this region at a copy
number of 2 is more common in patients with T1D for unknown
reasons. Determining expression levels of the genes encoded in this
region could begin to unravel the mystery of this CNVR.
In considering the overlap of enrichment and depletion of these
regions in additional autoimmune cohorts of RA and MS patients
we can assess contributions to autoimmunity. 2 CNPs found
enriched in the diabetes cohorts were also enriched in RA and
may be shared regions of susceptibility to peripheral, non-
neurologic autoimmunity. An additional 2 CNPs were enriched
in RA and MS and could be involved in general autoimmune
processes. Similarly, the 2 CNPs and 1 novel CNVR depleted in
all 3 autoimmune diseases may indicate that normal functioning in
these regions is also involved in general autoimmune processes.
In conclusion, 9 CNVs were found that are either enriched or
depleted in 2 independent cohorts of patients with or at high risk
for developing T1D. These regions may represent genetic variants
contributing to islet autoimmunity or disease onset and could be
used to assess risk of developing T1D. Knowledge of CNVs
associated with T1D risk and islet autoimmunity could also
improve our understanding of disease origins.
Materials and Methods
Ethics Statement
These studies were approved by the Institutional Review Board
of Vanderbilt University and all subjects provided written
informed consent. Monozygotic twin blood samples and family
history information were provided with written informed consent
using protocols and consent forms approved by the Colorado
Multiple Institutional Review Board.
Patient Recruitment
Diabetes is defined by the WHO criteria of classic symptoms of
diabetes (polydipsia, polyuria, polyphagia and weight loss) and a
plasma glucose .200 mg/dl, a fasting plasma glucose of .126
mg/dl or a 2 h plasma glucose during an oral glucose tolerance
Figure 2. Individual breakpoints of CNVR A588. Starting and ending points of each variant in a 1.3 mega base pair region on chromosome 15.
Below the x-axis are the gene coding regions (GCR) found in this portion of the genome.
doi:10.1371/journal.pone.0015393.g002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15393Figure 3. Frequencies of CNVs in other autoimmune diseases. Panel A. Frequency of CNPs identified as enriched in the T1D cohort in the Ctrl,
pooled T1D, RA and MS cohorts. Panel B. Frequency of CNVs identified as depleted in the T1D cohorts, in Ctrl, pooled T1D, RA and MS cohorts. Ctrl
n=19, T1D n=38, RA n=21, MS n=50. p-values determined by chi-square analysis, *=p,0.05, **=p,0.005 and ***=p,0.0005.
doi:10.1371/journal.pone.0015393.g003
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by a number of criteria- history, clinical presentation and
laboratory findings, including antibody testing when available.
Control patients have never received a diagnosis of a chronic disease
or syndrome and are not currently taking medication for any
illness or condition. Rheumatoid arthritis is defined by the American
College of Rheumatology Criteria. Patients displayed four or more
of the following symptoms for greater than 6 months: morning
stiffness, swelling in 3 or more joints, swelling of finger and/or
wrist joints, symmetric swelling, rheumatoid nodules, positive
rheumatoid factor, or radiographic erosions in the hand and/or
wrist[37]. Multiple Sclerosis patients were recruited with the
following characteristics: diagnosis of relapsing remitting MS
(RRMS) based upon the revised McDonald criteria[38,39], no
prior cytotoxic treatments that might induce DNA damage, no
family history of MS in either first or second degree relatives, and
age between 25–35 (to restrict the possibility of age-related somatic
mutations).
Ten pairs of monozygotic twins were selected from the Barbara
Davis Center Twin Family Study, an ongoing, long-term follow up
study of initially unaffected twins of patients with type 1 diabetes.
Twins are ascertained through various sources, including the
Barbara Davis Center Clinic, the Joslin Diabetes Clinic, the
Diabetes Prevention Trial, TrialNet, and other physician and self-
referrals. Family history of diabetes and other autoimmune
diseases is collected at enrollment and updated over time. Serum
and DNA samples are collected from twins and other family
members. Serum is tested for the presence of islet autoantibodies
as well as celiac and adrenal autoantibodies. Autoantibody testing
is repeated for unaffected twins for as long as they remain in the
study or until they develop diabetes. Twin zygosity is confirmed by
testing a panel of 16 microsatellite markers. Twin DNA samples
included in the present study were collected within 14 months of
diagnosis of the affected twin, and at approximately the same time
(within 1 week) for the two twins of each pair.
Genomic DNA samples from 73 patients with T1D, comprising
the independent cohort for qPCR analysis, were obtained from
Coriell Cell Repository, repository number 65895.
Affymetrix Copy Number Variation Experiments
Peripheral blood was drawn into a Vacutainer Venous Blood
Collection Tube (BD Catalog #367861) containing EDTA. Equal
volume of lysis buffer (0.32M Sucrose, 10 mM Tris-HCL, 5 mM
MgCl2, 0.75% Triton X-100, pH 7.6) and 2X volumes of dH20
were added to each. Samples were centrifuged and resuspended in
lysis buffer. After a second centrifugation, the pellet was
resuspended in proteinase K buffer (20 mM Tris-HCl, 4 mM
Na2-EDTA, 100 mM NaCl, pH 7.4) and proteinase K (20 mg/
ml) was added to the solution. Samples were incubated for 1 h at
55C, cooled on ice and 5.3M NaCl was added. Samples were
centrifuged, supernatants kept and added to cold isopropanol and
incubated for 30 minutes. Finally, genomic DNA was centrifuged
and the pellet was washed twice with 70% ethanol. Genomic DNA
was dissolved in Tris-HCl (pH 8.0).
Genomic DNA was hybridized to the Affymetrix Genome-Wide
Human SNP Array 6.0 (Santa Clara, CA) according to the
manufacturer’s protocol. Following scanning, arrays were checked
for quality using Affymetrix Genotyping Console. Arrays with a
Contrast QC less than 0.4 were removed from further analysis.
Genotypes and copy numbers were called using Birdsuite v1.5.3.
As a further quality control step, arrays with an overall call rate
less than 98% were discarded from further analysis.
Copy Number Analysis
Genomic regions with a Birdsuite copy number call confidence
value less than 5 were merged to the adjacent region with a
confidence score greater than 5, assuming the copy number of that
confident region. Next, each genome was narrowed down to a list
of genomic variants with confidence scores greater than 5. Regions
of CN=2 were discarded. These lists were merged with the list of
CNPs and regions of variance not represented by a CNP were
denoted as ‘‘novel’’ [28]. Next, CNVs that were present in greater
than 40% of the T1D group at a 1.5 fold change greater frequency
as compared to the Ctrl group were determined to be enriched
and CNVs present in greater than 40% of the Ctrl group at a 1.5
fold change greater frequency as compared to the T1D group
were determined to be depleted. For validation of these CNVs
whose presence or absence may be associated with diabetes, an
identical analysis was performed on the discordant twin cohort, as
compared to Ctrl and with the additional step of comparing the
affected twins versus their unaffected co-twin pair to determine
any variants present differentially within the group. CNVs
enriched or depleted in both the twins and unrelated T1D adults
were selected for further analysis. Chi-square analyses were
performed on each CNV of interest in each cohort versus control
based on the presence or absence of variance.
We assessed statistical significance for the observed overlapping
CNVs in both T1D cohorts relative to the Ctrl group using a
permutation test with 1000 permutations. Briefly, keeping the
number of patients fixed in each of the three groups, we randomly
permutated group status for the samples (so that they were re-
assigned to different groups) and re-calculated the number of
enriched CNVs in both disease groups relative to Ctrl. This
process was repeated 1000 times. The p-value for the number of
observed overlapping CNVs (i.e. 10) was estimated by the number
of permutations with 10 or more overlapping CNVs divided by the
total number of permutations.
Quantitative PCR Experiments
To validate the copy number of variant regions from the
Affymetrix chip, primer assays were ordered from Applied
Biosystems, selected from their inventoried stock of assays designed
specifically to detect genomic copy number. Reactions were run
with 20 ng genomic DNA per the standard Applied Biosystems
protocol in a 7300 Real Time PCR System. All samples were run
Figure 4. qPCR analysis of 3 T1D enriched CNPs in independent
cohorts. Frequency of variance is shown for an independent Ctrl
cohort (n=73) and an independent T1D cohort (n=73) at 3 CNP
locations. Copy number was determined by DDCt calculations from
qPCR data. p-values detemined by chi-square analysis.
doi:10.1371/journal.pone.0015393.g004
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number was called using Applied Biosystem’s CopyCaller v.1.0.
Supporting Information
Table S1 Raw Copy Number Calls derived from Affyme-
trix SNP 6.0 Arrays. Copy numbers were called across the
genome using the Birdsuite program. Tabs separate calls by group:
Control contains calls for the 19 unrelated adult control subjects,
Type 1 Diabetes contains calls for the 18 unrelated adults with
T1D, and Twin contains calls for the 10 pairs of monozygotic
twins, each pair denoted by the same number with letter a or b.
Additionally, confidence values below 5 are assumed to be invalid
calls in these studies. (XLS)
Table S2 Comparisons of Birdsuite Copy Number Calls
to qPCR calls. 185 unique gene region-sample comparisons
were made between the copy number as determined by Birdsuite
based on Affymetrix array data and copy number determined
independent of the array by qPCR. (XLS)
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